MD1716C2 - Utilizare a melatoninei pentru tratamentul pacienţilor dependenţi de benzodiazepine - Google Patents

Utilizare a melatoninei pentru tratamentul pacienţilor dependenţi de benzodiazepine Download PDF

Info

Publication number
MD1716C2
MD1716C2 MD97-0254A MD970254A MD1716C2 MD 1716 C2 MD1716 C2 MD 1716C2 MD 970254 A MD970254 A MD 970254A MD 1716 C2 MD1716 C2 MD 1716C2
Authority
MD
Moldova
Prior art keywords
benzodiazepine
melatonin
treatment
patient
patients dependent
Prior art date
Application number
MD97-0254A
Other languages
English (en)
Romanian (ro)
Russian (ru)
Other versions
MD970254A (en
MD1716B2 (en
Inventor
Nava Zisapel
Original Assignee
Neurim Pharmaceuticals (1991) Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/381,535 external-priority patent/US6469044B1/en
Application filed by Neurim Pharmaceuticals (1991) Ltd. filed Critical Neurim Pharmaceuticals (1991) Ltd.
Publication of MD970254A publication Critical patent/MD970254A/xx
Publication of MD1716B2 publication Critical patent/MD1716B2/xx
Publication of MD1716C2 publication Critical patent/MD1716C2/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MD97-0254A 1995-02-01 1996-01-29 Utilizare a melatoninei pentru tratamentul pacienţilor dependenţi de benzodiazepine MD1716C2 (ro)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/381,535 US6469044B1 (en) 1995-02-01 1995-02-01 Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
EP95303853A EP0724878B1 (de) 1995-02-01 1995-06-06 Verwendung von Melatonin zur Behandlung von Patienten die an Drogenabhängigkeit leiden
PCT/IB1996/000082 WO1996023496A1 (en) 1995-02-01 1996-01-29 Use of melatonin for treating patients suffering from drug addiction

Publications (3)

Publication Number Publication Date
MD970254A MD970254A (en) 1999-05-31
MD1716B2 MD1716B2 (en) 2001-08-31
MD1716C2 true MD1716C2 (ro) 2002-02-28

Family

ID=26140195

Family Applications (1)

Application Number Title Priority Date Filing Date
MD97-0254A MD1716C2 (ro) 1995-02-01 1996-01-29 Utilizare a melatoninei pentru tratamentul pacienţilor dependenţi de benzodiazepine

Country Status (22)

Country Link
JP (1) JP4516159B2 (de)
CN (1) CN1083263C (de)
AT (1) AT408188B (de)
AU (1) AU695366B2 (de)
BG (1) BG62876B1 (de)
BR (1) BR9607169A (de)
CZ (1) CZ291349B6 (de)
DK (1) DK176081B1 (de)
EE (1) EE03384B1 (de)
FI (1) FI119586B (de)
IS (1) IS1980B (de)
LU (1) LU90118B1 (de)
LV (1) LV11940B (de)
MD (1) MD1716C2 (de)
NO (1) NO312814B1 (de)
NZ (1) NZ298878A (de)
PL (1) PL183148B1 (de)
SI (1) SI9620022A (de)
SK (1) SK284521B6 (de)
TR (1) TR199700723T1 (de)
TW (1) TW483757B (de)
WO (1) WO1996023496A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150190A0 (en) 2000-01-05 2002-12-01 Neurim Pharma 1991 Method and formulation for treating resistance to antihypertensives and related conditions
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
IL330095A (en) 2012-01-26 2026-08-01 Vanda Pharmaceuticals Inc Tesimalta for use in the treatment of asynchronous circadian rhythm of cortisol
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
IL266159B2 (en) 2012-12-18 2024-07-01 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
DK3337462T3 (da) * 2016-10-31 2020-10-12 Neurim Pharma 1991 Melatonin-minitabletter og fremgangsmåde til fremstilling heraf

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0513702A2 (de) * 1991-05-13 1992-11-19 I.F.L.O. ISTITUTO FARMACOLOGICO LOMBARDO S.A.S. di Giorgio & Aldo Laguzzi & C. Melatoninderivate zur Behandlung von Schlafstörungen und zur Pre-Anästhesie
EP0518468A1 (de) * 1991-05-09 1992-12-16 Neurim Pharmaceuticals (1991) Limited Melatonin enthaltende Arzneimittel

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0518468A1 (de) * 1991-05-09 1992-12-16 Neurim Pharmaceuticals (1991) Limited Melatonin enthaltende Arzneimittel
EP0513702A2 (de) * 1991-05-13 1992-11-19 I.F.L.O. ISTITUTO FARMACOLOGICO LOMBARDO S.A.S. di Giorgio & Aldo Laguzzi & C. Melatoninderivate zur Behandlung von Schlafstörungen und zur Pre-Anästhesie

Also Published As

Publication number Publication date
PL183148B1 (pl) 2002-05-31
CZ240597A3 (cs) 1998-01-14
BR9607169A (pt) 1997-11-11
PL321630A1 (en) 1997-12-08
EE9700166A (et) 1998-02-16
ATA901396A (de) 2001-02-15
JP4516159B2 (ja) 2010-08-04
SK284521B6 (sk) 2005-05-05
FI973185A0 (fi) 1997-07-31
MD970254A (en) 1999-05-31
SI9620022A (sl) 1998-10-31
TW483757B (en) 2002-04-21
TR199700723T1 (xx) 1998-02-21
EE03384B1 (et) 2001-04-16
NZ298878A (en) 1999-05-28
IS1980B (is) 2005-01-14
DK89697A (da) 1997-07-30
MX9705856A (es) 1998-07-31
AU4457496A (en) 1996-08-21
FI119586B (fi) 2009-01-15
SK103097A3 (en) 1998-01-14
JPH10513177A (ja) 1998-12-15
CN1083263C (zh) 2002-04-24
BG101803A (en) 1998-04-30
NO973531L (no) 1997-09-30
WO1996023496A1 (en) 1996-08-08
CZ291349B6 (cs) 2003-02-12
CN1172431A (zh) 1998-02-04
LV11940A (lv) 1998-01-20
AT408188B (de) 2001-09-25
MD1716B2 (en) 2001-08-31
LV11940B (en) 1998-05-20
FI973185L (fi) 1997-09-30
DK176081B1 (da) 2006-04-18
AU695366B2 (en) 1998-08-13
IS4532A (is) 1997-07-25
NO973531D0 (no) 1997-07-31
NO312814B1 (no) 2002-07-08
BG62876B1 (bg) 2000-10-31
LU90118B1 (fr) 1997-11-13

Similar Documents

Publication Publication Date Title
CY2007001I2 (el) Φαρμακευτικο σκευασμα για χρηση στη θεραπεια του διαβητη
ES2165910T3 (es) Administracion nasal y ocular de cetamina para el tratamiento del dolor y para la desintoxicacion.
KR960700059A (ko) 파킨슨씨 병 및 파킨슨 중후군의 치료에 카르바마제핀 및 옥스카르바제핀의 이용(application of carbamazepine and oxcarbazepine in the treatment of parkinson's disease and parkinsonian syndromes)
ATE127804T1 (de) Pharmazeutische verbindungen.
PT1025845E (pt) Terapia com hidromorfona
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
BRPI0009719B8 (pt) processo de tratamento
HUP9802091A2 (hu) Idegátültetés pluripotens neuroepiteliális sejtek alkalmazásával
DE69617729D1 (de) Verwendung von antimineralcorticoidverbindungen gegen das drogenentzugssyndrom
EE9700302A (et) Meetod maania ja bipolaarse häire raviks
TR200001040T2 (tr) Kaşıntıyı önleme etkisi için bileşiklerin yeni bir kullanımı
ATE202599T1 (de) Mit isoliertem empfindlichem x-syndrom verbundene dns-sequenzen
KR950701221A (ko) 물질 남용 장해 치료제
HUP9802423A2 (hu) Hiperproliferatív megbetegedések kombinált gyógyászati kezelése
FI874166A7 (fi) 2',3'-dideoksisytidin-2'-eenin käyttö retroviruksilla infektoituneiden potilaiden hoitoon.
BR0009380A (pt) Tratamento de câncer melhorado comtemozolomida
MD1716B2 (en) Use of melatonin for treatment of patients dependent on benzodiazepine
AU1463088A (en) Receptor of the small rhinovirus receptor group
NO990450L (no) Behandling av sinnslidelser
PT869785E (pt) 4-hidroxicumarina-3-carboxamidas para o tratamento de diabetes mellitus nao insulinodependente
NO984651L (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
NZ307601A (en) Use of a pharmaceutically acceptable oxalate derivative in the manufacture of a medicament for the treatment of skin conditions
ATE207357T1 (de) Verwendung von cotinin zur linderung des tabakentzugssyndrom
NO960545D0 (no) Behandling av skadelige virkninger i forbindelse med administrering av ekstracellulært hemoglobin
KR960003718A (ko) 말초신경병 및 중추신경변성병의 치료에 유용한 의약의 제조를 위한 이펜프로딜 및 그 부분입체이성질체의 이용

Legal Events

Date Code Title Description
PD99 Pending application
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees